These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33103699)

  • 1. Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials.
    Virumbrales-Muñoz M; Chen J; Ayuso J; Lee M; Abel EJ; Beebe DJ
    Lab Chip; 2020 Nov; 20(23):4420-4432. PubMed ID: 33103699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-specific organotypic blood vessels as an in vitro model for anti-angiogenic drug response testing in renal cell carcinoma.
    Jiménez-Torres JA; Virumbrales-Muñoz M; Sung KE; Lee MH; Abel EJ; Beebe DJ
    EBioMedicine; 2019 Apr; 42():408-419. PubMed ID: 30902740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy.
    Virumbrales-Muñoz M; Ayuso JM; Loken JR; Denecke KM; Rehman S; Skala MC; Abel EJ; Beebe DJ
    Biomaterials; 2022 Apr; 283():121454. PubMed ID: 35299086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
    Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
    Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
    Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
    PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexity of tumor vasculature in clear cell renal cell carcinoma.
    Qian CN; Huang D; Wondergem B; Teh BT
    Cancer; 2009 May; 115(10 Suppl):2282-9. PubMed ID: 19402071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 3D Human Renal Cell Carcinoma-on-a-Chip for the Study of Tumor Angiogenesis.
    Miller CP; Tsuchida C; Zheng Y; Himmelfarb J; Akilesh S
    Neoplasia; 2018 Jun; 20(6):610-620. PubMed ID: 29747161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.
    Pilskog M; Bostad L; Edelmann RJ; Akslen LA; Beisland C; Straume O
    J Pathol Clin Res; 2018 Apr; 4(2):114-123. PubMed ID: 29665322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of Manic fringe impedes angiogenesis and cell migration of renal carcinoma.
    Cheng WK; Oon CE; Kaur G; Sainson RCA; Li JL
    Microvasc Res; 2022 Jul; 142():104341. PubMed ID: 35157839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serous neoplasms of the pancreas share many, but not all aspects of their microvascular and angiogenic profile with low-grade clear cell renal cell carcinomas.
    Liszka Ł; Pająk J; Gołka D
    Pathol Res Pract; 2014 Dec; 210(12):901-8. PubMed ID: 25155377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.
    Cai Q; Christie A; Rajaram S; Zhou Q; Araj E; Chintalapati S; Cadeddu J; Margulis V; Pedrosa I; Rakheja D; McKay RM; Brugarolas J; Kapur P
    EBioMedicine; 2020 Jan; 51():102526. PubMed ID: 31859241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma.
    Wang G; Li H; Hou Y
    Cancer Gene Ther; 2022 May; 29(5):585-596. PubMed ID: 34002044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
    Rosen MA; Schnall MD
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy.
    Rustum YM; Reis R; Rustum TM
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peculiarities of angiogenesis in clear cell renal cancer].
    Maiborodin IV; Klimachev IV; Sheplev BV; Krasil'nikov SE; Maiborodina VI
    Arkh Patol; 2024; 86(4):64-70. PubMed ID: 39073545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.